Key result
Increased plasma Lp-PLA2 levels were independently associated with the presence of coronary slow flow after adjustment for conventional risk factors (OR 1.040).
Why the study?
Whether lipoprotein-associated phospholipase A2 (Lp-PLA2) serves as a significant predictive factor for coronary slow flow remains controversial.
Are increased plasma Lp-PLA2 levels associated with coronary slow flow in patients undergoing coronary angiography?
Observational (n=170)
No
Are increased plasma Lp-PLA2 levels associated with coronary slow flow in patients undergoing coronary angiography?
Odds Ratio: 1.04 (95% CI 1.022–1.059)
p-value: p=<0.001
Increased plasma Lp-PLA2 levels are independently associated with the presence and severity of coronary slow flow, suggesting its potential utility as a predictive biomarker.
Elevated Lp-PLA2 was associated with CSF; hypothesis-generating and requires prospective validation before clinical use.
Objective Coronary slow flow (CSF) is characterized by delayed opacification of distal epicardial coronary arteries without significant coronary stenosis. In addition, The changes of lipoprotein-associated phospholipase A2 (Lp-PLA2) as a significant predictive factor for CSF remain controversial. The study aims to investigate the association between plasma Lp-PLA2 and CSF. Methods In this retrospective study, 170 consecutive patients who underwent coronary angiography were enrolled in Beijing Anzhen Hospital from January 2017 to September 2019, and were divided into CSF group and normal control groups. According to coronary blood flow rate measured by the thrombolysis in myocardial infarction frame count (TFC) method, CSF was defined as TFC > 27. Serum Lp-PLA2 levels were measured in an enzyme-linked immunosorbent assay. Results Lp-PLA2 levels were higher in the CSF group than in the control group (288.6 ± 50.3 versus 141.9 ± 49.7, P < 0.001) and were significantly correlated with the mean coronary artery thrombolysis in myocardial infarction (TIMI) frame count (r = 0.790, P<0.001). Logistic regression analysis showed that high Lp-PLA2 was independently associated with CSF after adjustment for conventional risk factors (OR = 1.040, CI = 1.022–1.059, P<0.001). Male sex (OR = 2.192, CI = 1.161–4.140, P = 0.016) and hypertension (OR = 1.965, CI = 1.034–3.736, P = 0.039) were also CSF risk factors. Receiver-operating characteristic curve (ROC) analysis showed that Lp-PLA2 levels can predict CSF severity; the predictive power was higher than the other risk factors. Conclusion Our study demonstrated that patients with CSF had higher circulating levels of Lp-PLA2 than normal controls. After adjustment for potential confounders, increased Lp-PLA2 was independently associated with presence of CSF.
No takes yet. Share an insight, caveat, or question.
Ding et al. (2020) conducted an observational in Coronary slow flow (n=170). Plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) levels vs. Lower Lp-PLA2 levels was evaluated on Presence of coronary slow flow (OR 1.040, 95% CI 1.022-1.059, p=<0.001). Increased plasma Lp-PLA2 levels were independently associated with the presence of coronary slow flow after adjustment for conventional risk factors (OR 1.040).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: